Navigation Links
WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry
Date:10/10/2010

SHANGHAI, Oct. 10 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today extended its congratulations to Dr. Richard Heck, Dr. Ei-ichi Negishi, and Dr. Akira Suzuki on winning the 2010 Nobel Prize in Chemistry. The prize was awarded for the development of palladium-catalyzed cross coupling, which has vastly improved the ability of chemists to create sophisticated chemical compounds. Dr. Negishi spoke at WuXi headquarters in July in the company's Science Seminar Series.

Dr. Negishi graduated from the University of Tokyo in 1958 and did his internship at Teijin Ltd., a Japanese pharmaceutical and chemical company. He earned a Ph.D. from the University of Pennsylvania in 1963 under the supervision of Dr. Allan Day. In 1966, he became a postdoctoral researcher at Purdue University, and he served as assistant to Nobel laureate Dr. Herbert Brow beginning in 1968. He was appointed assistant professor of chemistry at Syracuse University in 1972 and full professor at Purdue University in 1979. Dr. Negishi is the author or co-author of more than 375 papers, 30 essays, and two books.

WuXi scientists were highly impressed by Dr. Negishi's lectures in July, titled "Evolution of the Pd-Catalyzed Cross-Coupling for C-C Bond Formation: Complementary with the Grignard Chemistry" and "Zirconium-Catalyzed Asymmetric Carboalumination of Alkenes." The WuXi PharmaTech Science Seminar Series is a monthly program that invites the world's top scientific minds and leaders in the pharmaceutical industry to speak to the company's scientists. The program aims to keep them informed about the latest developments in a broad range of topics in pharmaceutical research and development.

"Congratulations to Dr. Negishi, Dr. Heck, and Dr. Suzuki on w
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
2. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
8. WuXi PharmaTech Announces Third Quarter 2008 Results
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
11. Pharmatech 2.0: Introducing Pharmatech Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... The Thomas Brain Health Center ... groundbreaking pilot study to see if early Alzheimer’s ... little as three to six months. , The ... medicine—will aggressively target and simultaneously treat the numerous ... brain. These include oxidative stress, neuroinflammation, mitochondrial dysfunction, ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Data Presented Today at American Society of Clinical Oncology ... Therapeutics, Inc. today presented data demonstrating the use of ... cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual ... the 54 primary colorectal cultures tested, eight percent were ...
... of response up to week 26 in moderate to ... infliximab. , , CHICAGO, June 1 New ... the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab ... week 26 for adult patients suffering from moderate to ...
... SOUTH PLAINFIELD, N.J., June 1 PTC Therapeutics, Inc. ... as Vice President of Commercial Operations. In this ... President, Commercial, and will be responsible for PTC,s patient ... reimbursement. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... School of Medicine of the University of Southern California ... female sex hormone, activates genes in breast-cancer cells. Greater ... lead to new treatments for the disease. ... Keck School,s Department of Biochemistry and Molecular Biology, was ...
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... PARIS, Nov. 15, 2011 DigitalPersona, ... and endpoint protection solutions, today announced the availability ... biometric device manufacturers and solution providers. FingerJet OEM ... along with fast one-to-many identification and one-to-one verification. ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2TWAS 22nd General Meeting in Trieste 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 3
...
Ezrin/Radixin/Moesin Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Biology Products: